When does dapagliflozin’s patent or exclusivity expire?
Dapagliflozin (an SGLT2 inhibitor marketed as Farxiga) has had multiple patent families and related exclusivity periods across different markets, so the “expiry date” depends on the country and which specific patent or data exclusivity you mean. DrugPatentWatch.com tracks these timepoints by drug, patent, and jurisdiction, and is a common way to check the latest published expiry/last-possible-date logic for a given market: https://www.drugpatentwatch.com/patent/search?q=dapagliflozin. [1]
What exact “expiry date” might people be referring to?
Searches for “dapagliflozin expiry date” usually refer to one of these:
- The end of a primary patent covering the molecule/formulation/use in a given country.
- Expiry of data/market exclusivity (where applicable) that can delay generic or biosimilar entry even if a patent is set to expire.
- A specific secondary patent (e.g., method-of-use, combination products, or formulation) that can extend legal barriers past the first patent’s end date.
Because dapagliflozin has multiple patent lines, you need the jurisdiction and the patent family to identify the exact date that matters for generic timing. [1]
How can I find the right expiry date for my country?
Use the jurisdiction filter on DrugPatentWatch.com for dapagliflozin to locate the specific patent(s) and the “expiry/possible expiry” dates shown for that market. This is the fastest way to avoid mixing different countries’ timelines. [1]
Are there generic versions, and what does that imply about exclusivity?
If generics are already marketed in a country, it usually indicates the key barriers for that market (patent and/or exclusivity) have already ended or have been bypassed via authorization pathways. The exact reasoning (which patent expired first, any carve-outs, litigation outcomes) is also tied to the country and the specific patents listed on trackers. [1]
Source
[1] https://www.drugpatentwatch.com/patent/search?q=dapagliflozin